📰 Immunic News
Page 4 - Immunic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic. Real-time updates on events, politics, business and more.
May 22, 2023
StockNews.com assumed coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research report sent to investors on Thursday morning. The firm issued a sell rating on the stock. Separately, Wedbush reiterated an outperform rating and issued a $5.00 price objective on shares of Immunic in a report on Tuesday, January 31st. One investment […]
May 21, 2023
StockNews.com started coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research report report published on Thursday morning. The firm issued a sell rating on the stock. Separately, Wedbush restated an outperform rating and set a $5.00 target price on shares of Immunic in a report on Tuesday, January 31st. One investment analyst […]
May 17, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
May 17, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1 […]
May 17, 2023
Issuer: Immunic, Inc. / Key word(s): Scientific publication Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
May 16, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 3,650,000 shares, a decrease of 14.7% from the April 15th total of 4,280,000 shares. Based on an average trading volume of 1,310,000 shares, the short-interest […]
May 16, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totalling 3,650,000 shares, a decline of 14.7% from the April 15th total of 4,280,000 shares. Based on an average trading volume of 1,310,000 shares, the days-to-cover ratio is presently […]
May 16, 2023
<iframe src=https://www.youtube.com/embed/-1tdPdVJr_M></iframe>Dr Daniel Vitt, CEO of Immunic Inc , discusses the companys encouraging first-quarter performance with Proactive.The... | May 16, 2023
May 11, 2023
Immunic (NASDAQ:IMUX – Get Rating) and ObsEva (NASDAQ:OBSV – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation. Institutional and Insider Ownership 60.7% of Immunic shares are held by […]
May 11, 2023
NEW YORK — NEW YORK — Immunic, Inc. on Thursday reported a loss of $25.3 million in its first quarter. On a per-share basis, the New York-based company said it had a loss of 58... | May 11, 2023